EcoR1 Capital LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 5.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,451,647 shares of the company’s stock after purchasing an additional 268,216 shares during the quarter. Apellis […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) insider Pascal Deschatelets sold 12,000 shares of the stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $42.87, for a total value of $514,440.00. Following the transaction, the insider now owns 1,059,813 shares in the company, valued […]
Apellis Pharmaceuticals (NASDAQ: APLS) has recently received a number of price target changes and ratings updates: 8/30/2023 – Apellis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock. 8/29/2023 – Apellis Pharmaceuticals had its price target raised by analysts at Citigroup […]
Apellis Pharmaceuticals (NASDAQ:APLS) Earns Buy Rating from Needham & Company LLC theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a note issued to investors on Wednesday, Benzinga reports. They presently have a $60.00 price target on the stock. Needham & Company LLC’s target price suggests a potential upside of 42.15% from the […]